Early and convenient diagnosis is urgently needed for acute Stanford type A aortic dissection (AAAD) patients due to its high mortality within the first 48 hours. Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular diseases， however， little is known about circulating miRNAs involved in AAAD. Here， the blood serum was sampled from 104 AAAD+ patients and 103 age-matched donors. Initial screening was conducted using the TaqMan Low Density Array followed by RT-qPCR confirmation. According to the two-phase selection and validation process， we found that miR-25， miR-29a and miR-155 were significantly elevated， while miR-26b was markedly decreased in AAAD+ serum samples compared wit... More
Early and convenient diagnosis is urgently needed for acute Stanford type A aortic dissection (AAAD) patients due to its high mortality within the first 48 hours. Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular diseases， however， little is known about circulating miRNAs involved in AAAD. Here， the blood serum was sampled from 104 AAAD+ patients and 103 age-matched donors. Initial screening was conducted using the TaqMan Low Density Array followed by RT-qPCR confirmation. According to the two-phase selection and validation process， we found that miR-25， miR-29a and miR-155 were significantly elevated， while miR-26b was markedly decreased in AAAD+ serum samples compared with AAAD- individuals. Most importantly， for individuals with hypertension， which is a major contributor to AAAD， the 4-miRNA panel also showed high accuracy in predicting those who are more likely to develop AAAD. In the blind trial set， the panel correctly classified 93.33% AAAD+ patients and 86.67% controls from the hypertension cohort. Finally， the serum miRNA-based biomarker for early AAAD detection was supported by a retrospective analysis. Taken together， we identify a distinct profile of 4-miRNA that can serve as a noninvasive biomarker for AAAD diagnosis， especially for those with hypertension.
